R 142440
Latest Information Update: 13 May 2008
At a glance
- Originator Daiichi Sankyo Company
- Class
- Mechanism of Action Osteoprotegerin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 07 Apr 2006 Preclinical trials in Osteoporosis in Europe (Injection)
- 07 Apr 2006 Preclinical trials in Osteoporosis in USA (Injection)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc